![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, January 03, 2011 9:30:28 AM
BERKELEY, Calif., Nov. 4, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its financial results for the third quarter ended September 30, 2010 and provided a general business update.
"The next several months will see pivotal events in the development of our flagship anti-inflammatory antibody candidate, XOMA 052, for Type 2 diabetes," said Steven B. Engle, XOMA's Chairman and Chief Executive Officer. "We expect to announce interim results from three months of treatment in our 74 patient Phase 2a clinical trial in early January. During the first quarter of 2011, we plan to release top line results from our 420 patient Phase 2b trial, which is designed to evaluate the activity of XOMA 052 in diabetes patients over six months of treatment. Positive results could bring a potentially disease-modifying therapeutic for the treatment of Type 2 diabetes a major step closer to patients."
Financial Results
XOMA had total revenues of $10.9 million and a net loss of $13.6 million, or $0.69 per share, in the third quarter of 2010, compared with total revenues of $27.4 million and net income of $1.5 million, or $0.13 per share, in the third quarter of 2009. The decrease in revenues in the 2010 period compared with the 2009 period was primarily due to the $25.0 million sale of the company's royalty interest in LUCENTIS® in the third quarter of 2009, partially offset by increased contract revenue related to work performed under a U.S. government biodefense contract and the $4.0 million sale of the company's royalty interest in CIMZIA® in the 2010 third quarter.
XOMA had total operating expenses of $27.5 million in the quarter ended September 30, 2010, compared with $20.6 million in the 2009 third quarter. Research and development expenses were $21.3 million in the 2010 third quarter, compared with $13.4 million in the 2009 third quarter, primarily reflecting increased spending on the XOMA 052 Phase 2 clinical program. Selling, general and administrative expenses were $6.2 million in the 2010 third quarter compared with $7.2 million in the 2009 third quarter.
At September 30, 2010, XOMA had cash and cash equivalents of $16.9 million, compared with $23.9 million at December 31, 2009. Subsequent to September 30, 2010, XOMA's cash position was strengthened by $2.0 million received as final payment under its antibody discovery collaboration with Kaketsuken and $1.5 million in gross proceeds from equity issuances under an At Market Sales Agreement entered into in 2009 which has now been fully utilized. In addition, XOMA was awarded $977,917 in grants under the U.S. government's Patient Protection and Affordable Care Program.
Recent Highlights
Enrollment completed in Phase 2a trial of XOMA 052 in patients with Type 2 diabetes: This randomized, placebo-controlled trial, in which 74 patients were enrolled, is designed to evaluate extended biologic activity and safety of XOMA 052. Outcomes will include diabetes measures such as hemoglobin A1c, or HbA1c, and fasting blood glucose, or FBG, and C-reactive protein, or hsCRP, a biomarker of inflammation associated with cardiovascular risk. Interim results from the first three months of treatment in this six month trial are expected to be announced in the first half of January 2011.
Enrollment completed in Phase 2b trial of XOMA 052 in patients with Type 2 diabetes: This randomized, placebo-controlled dose-ranging trial enrolled 420 patients and is designed to further evaluate the safety and efficacy of XOMA 052 dosed once monthly compared to placebo. The results will include data on measurements of HbA1c, FBG and hsCRP. Top line results are expected to be announced in the first quarter of 2011.
XOMA 052 designated orphan drug in U.S. and European Union for the treatment of Behcet's disease: Orphan drug designation generally provides multi-year marketing exclusivity and other potential advantages for the development of new agents to treat rare diseases. In June 2010, XOMA announced positive results from an open-label pilot study of XOMA 052 in seven patients with Behcet's disease who were suffering from vision-threatening disease exacerbations, known as uveitis, despite maximal doses of immunosuppressive medicines. XOMA 052 was well-tolerated in this trial, and improvements in vision and ocular inflammation were observed in all seven patients following initial treatment, and in each of the five retreated patients.
$4 million received from sale of rights to CIMZIA® royalties and $750,000 milestone payment received from AVEO: The proceeds of the sale and milestone payment provide non-dilutive funding to support the development of XOMA 052 and other programs.
$997,917 in grants awarded under the Patient Protection and Affordable Care program: All four of the applications XOMA submitted under this program were awarded to the maximum allocation, providing non-dilutive capital to advance XOMA's programs to develop XOMA 052, XOMA 3AB, and monoclonal antibody therapeutics for the treatment of metabolic and oncologic diseases. The award payments were authorized on October 29, 2010.
Additional Financial Results
Interest expense for the third quarter of 2010 was $0.1 million compared with $1.3 million for the same period of 2009. The decrease in the 2010 period compared with the 2009 period was primarily due to the repayment in full of the term loan with Goldman Sachs Specialty Lending Holdings, Inc. in September 2009. Other income was $3.1 million in the 2010 third quarter compared with $0.1 million in the third quarter of 2009. This increase was primarily related to revaluation of warrant liabilities in the third quarter of 2010.
Liquidity and Capital Resources
Net cash used in operations during the first nine months of 2010 was $42.9 million compared with cash provided by operations of $11.5 million for the same period in 2009. The decrease in cash provided by operating activities in the 2010 period was primarily due to a decrease in revenue receipts for license and collaborative fees and royalties and an increase in spending on the XOMA 052 Phase 2 clinical program.
In October 2010, XOMA entered into an At Market Issuance Sales Agreement under which XOMA may issue shares from time to time through Wm Smith & Co. and McNicoll, Lewis & Vlak LLC as agents by means of one or more "at the market" offerings or, with XOMA's approval, in negotiated transactions. This agreement replaces the At Market Sales Agreement XOMA entered into in the 2009 third quarter, which has been fully utilized.
Guidance
XOMA will not be providing specific guidance on overall revenues or cash receipts for 2010 so as to best manage its ongoing negotiations for XOMA 052 and technology licensing. Excluding potential revenue from business development activities, the company expects that up to $60 million in cash may be used in operating activities in 2010.
Reverse Stock Split and NASDAQ Compliance
On August 18, 2010, XOMA effected a 1-for-15 share consolidation, or reverse stock split. In September 2010, NASDAQ notified the Company that it regained compliance with the minimum $1.00 per share bid price requirement for continued listing on The NASDAQ Global Market.
Investor Conference Call
XOMA will host a conference call and webcast to discuss its first quarter 2010 financial results today, November 4, 2010, at 4:30 pm ET. The webcast can be accessed via the Investors section of XOMA's website at http://investors.xoma.com/events.cfm and will be available for replay until close of business on February 2, 2011.
About XOMA
XOMA discovers, develops and manufactures novel antibody therapeutics for its own proprietary pipeline as well as through license and collaborative agreements with pharmaceutical and biotechnology companies, and under its contracts with the U.S. government. The company's proprietary product pipeline includes:
XOMA 052, an anti-IL-1 beta antibody in Phase 2 clinical development for Type 2 diabetes with cardiovascular biomarkers, Type 1 diabetes, and with potential for the treatment of a wide range of inflammatory conditions. XOMA 052 also has demonstrated positive clinical benefit in a proof-of-concept trial for the treatment of vision-threatening uveitis of Behcet's disease.
XOMA 3AB, an antibody candidate in pre-IND studies to neutralize the botulinum toxin, among the most deadly potential bioterror threats, under development through funding provided by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (Contract # HHSN266200600008C).
A preclinical pipeline with candidates in development for autoimmune, inflammatory and oncologic diseases.
In addition to its proprietary pipeline, XOMA develops products with premier pharmaceutical companies including Novartis AG, Schering Corporation, a subsidiary of Merck & Co., Inc., and Takeda Pharmaceutical Company Limited.
XOMA's technologies have contributed to the success of marketed antibody products, including LUCENTIS® (ranibizumab injection) for wet age-related macular degeneration and CIMZIA® (certolizumab pegol) for rheumatoid arthritis and Crohn's disease.
The company has a premier antibody discovery and development platform that incorporates an unmatched collection of antibody phage display libraries and proprietary Human Engineering(tm), affinity maturation, Bacterial Cell Expression (BCE) and manufacturing technologies. BCE is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. As a result, sixty pharmaceutical and biotechnology companies have signed BCE licenses, and several licensed product candidates are in clinical development.
XOMA has a fully integrated product development infrastructure, extending from pre-clinical science to approval, and a team of about 225 employees at its Berkeley, California location. For more information, please visit http://www.xoma.com.
The XOMA Ltd. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5960
Safe Harbor Statement
Certain statements contained herein concerning timing of results of clinical trials or other aspects of product development, or that otherwise relate to future periods, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market.
Among other things, the timing of results of clinical trials may be delayed or may never become available as a result of complications in the collection or interpretation of statistical data, unavailability of resources, actions or inaction by our present or future collaboration partners, insufficient enrollment in such trials or unanticipated safety issues; and results of clinical trials may in any event not be consistent with preclinical or interim results.
These and other risks, including the generally unstable nature of current economic conditions; the results of discovery research and preclinical testing; the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the FDA, European or other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data); uncertainties regarding the status of biotechnology patents; uncertainties as to the cost of protecting intellectual property; changes in the status of the existing collaborative and licensing relationships; the ability of collaborators, licensees and other third parties to meet their obligations; market demand for products; scale up and marketing capabilities; competition; international operations; share price volatility; XOMA's financing needs and opportunities; and risks associated with XOMA's status as a Bermuda company, are described in more detail in XOMA's most recent annual report on Form 10-K and in other SEC filings. Consider such risks carefully in considering XOMA's prospects.
Tables follow —
XOMA Ltd.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share amounts)
Three months ended
September 30, Nine months ended
September 30,
2010 2009 2010 2009
Revenues:
License and collaborative fees $ 1,410 $1,421 $ 1,749 $29,276
Contract and other revenue 5,733 3,688 18,025 18,662
Royalties 3,754 22,314 4,267 28,895
Total revenues 10,897 27,423 24,041 76,833
Operating expenses:
Research and development 21,345 13,444 58,278 43,472
Selling, general and administrative 6,152 7,197 16,731 18,972
Restructuring 45 2 45 3,603
Total operating expenses 27,542 20,643 75,054 66,047
(Loss) income from operations (16,645) 6,780 (51,013) 10,786
Other income (expense):
Investment and interest income 4 9 13 47
Interest expense (104) (1,339) (281) (4,778)
Loss on debt extinguishment -- (3,645) -- (3,645)
Other income (expense) 3,113 103 300 1,240
Net (loss) income before taxes (13,632) 1,908 (50,981) 3,650
Provision for income tax expense (benefit) 1 370 17 6,083
Net loss $(13,633) $1,538 $(50,998) $ (2,433)
Basic net (loss) income per common share $ (0.69) $ 0.14 $ (2.87) $ (0.24)
Diluted net (loss) income per common share $ (0.69) $ 0.13 $ (2.87) $ (0.24)
Shares used in computing basic net (loss) income per common share 19,802 11,150 17,742 10,211
Shares used in computing diluted net (loss) income per common share 19,802 11,517 17,742 10,211
XOMA Ltd.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
September 30,
2010 December 31,
2009
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $ 16,860 $ 23,909
Trade and other receivables, net 7,944 7,231
Prepaid expenses and other current assets 1,486 1,012
Total current assets 26,290 32,152
Property and equipment, net 16,179 20,270
Other assets 543 402
Total assets $ 43,012 $ 52,824
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 5,706 $ 2,942
Accrued liabilities 8,187 8,639
Deferred revenue 2,152 2,114
Warrant liabilities 1,716 4,760
Other current liabilities -- 223
Total current liabilities 17,761 18,678
Deferred revenue — long-term 1,346 2,894
Interest bearing obligation — long-term 13,505 13,341
Other long-term liabilities 353 385
Total liabilities 32,965 35,298
Shareholders' equity 10,047 17,526
Total liabilities and shareholders' equity $ 43,012 $ 52,824
CONTACT: XOMA Ltd.
Company and Investor Contact:
Carol DeGuzman
510-204-7270
deguzman@xoma.com
Canale Communications
Media Contact:
Carolyn Hawley
619-849-5375
carolyn@canalecomm.com
Recent XOMA News
- XOMA Declares Quarterly Preferred Stock Dividends • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher • GlobeNewswire Inc. • 06/12/2024 11:30:00 AM
- XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2% • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) • GlobeNewswire Inc. • 04/25/2024 11:30:00 AM
- Actym Therapeutics Appoints Thomas Smart as CEO • PR Newswire (US) • 04/24/2024 01:00:00 PM
- XOMA Corporation Announces Closing of Tender Offer • GlobeNewswire Inc. • 04/03/2024 01:00:00 PM
- XOMA Declares Quarterly Preferred Stock Dividends • GlobeNewswire Inc. • 03/21/2024 11:30:00 AM
- XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. • GlobeNewswire Inc. • 03/19/2024 08:05:00 PM
- XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value • GlobeNewswire Inc. • 03/08/2024 12:30:00 PM
- XOMA to Present at Upcoming Investor Conferences in March • GlobeNewswire Inc. • 02/28/2024 12:30:00 PM
- XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right • GlobeNewswire Inc. • 02/16/2024 01:00:00 PM
- XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition • GlobeNewswire Inc. • 01/18/2024 01:30:00 PM
- Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol • Dow Jones News • 01/11/2024 09:50:00 PM
- FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx • GlobeNewswire Inc. • 01/11/2024 09:05:00 PM
- XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors • GlobeNewswire Inc. • 01/08/2024 12:30:00 PM
- XOMA Announces Stock Repurchase Program of up to $50 Million • GlobeNewswire Inc. • 01/02/2024 12:30:00 PM
- XOMA Declares Quarterly Preferred Stock Dividends • GlobeNewswire Inc. • 12/20/2023 12:30:00 PM
- XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties • GlobeNewswire Inc. • 12/19/2023 12:30:00 PM
- XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value • GlobeNewswire Inc. • 11/07/2023 12:30:00 PM
- XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) • GlobeNewswire Inc. • 10/31/2023 11:30:00 AM
- XOMA Declares Quarterly Preferred Stock Dividends • GlobeNewswire Inc. • 09/25/2023 11:30:00 AM
- XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/06/2023 11:30:00 AM
- XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy • GlobeNewswire Inc. • 08/08/2023 11:30:00 AM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM